Optimal Radiation Dose for Stage III Lung Cancer—Should “Definitive” Radiation Doses Be Used in the Preoperative Setting?
Saffarzadeh AG, Canavan M, Resio BJ, Walters SL, Flores KM, Decker RH, Boffa DJ. Optimal Radiation Dose for Stage III Lung Cancer—Should “Definitive” Radiation Doses Be Used in the Preoperative Setting? JTO Clinical And Research Reports 2021, 2: 100201. PMID: 34590044, PMCID: PMC8474436, DOI: 10.1016/j.jtocrr.2021.100201.Peer-Reviewed Original ResearchLong-term mortality riskStage III NSCLCLow dosePreoperative settingMortality riskHigh doseRadiation doseClinical stage III patientsNational Cancer Database dataStage III lung cancerStage III patientsUse of surgeryLength of stayGy of radiationCox proportional hazardsComparative effectiveness analysisOptimal radiation doseSingle-dose strategyLong-term survivalRadiation dosesLogistic regression modelsDefinitive chemoradiotherapyN2 patientsNonsurgical patientsPerioperative outcomesThe Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases
Salazar MC, Canavan ME, Walters SL, Chilakamarry S, Ermer T, Blasberg JD, Yu JB, Gross CP, Boffa DJ. The Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases. JTO Clinical And Research Reports 2021, 2: 100143. PMID: 34590002, PMCID: PMC8474228, DOI: 10.1016/j.jtocrr.2021.100143.Peer-Reviewed Original ResearchStage I NSCLCWedge resectionSurveillance EpidemiologyMortality riskHigh riskSurvival advantageLife expectancyNational Cancer Institute's Surveillance EpidemiologyEnd Results-MedicareTreatment-naive patientsEarly-stage NSCLCRetrospective cohort studySuperior local controlShort life expectancyLife expectancy decreasesPerioperative complicationsCohort studyComorbid conditionsLung parenchymaLobectomyCox modelReasonable optionPatientsNSCLCLocal control